Last $26.12 USD
Change Today +1.95 / 8.07%
Volume 1.2M
SGNT On Other Exchanges
Symbol
Exchange
NASDAQ GS
Berlin
As of 8:10 PM 12/19/14 All times are local (Market data is delayed by at least 15 minutes).

sagent pharmaceuticals inc (SGNT) Snapshot

Open
$24.11
Previous Close
$24.17
Day High
$26.29
Day Low
$24.01
52 Week High
10/14/14 - $33.60
52 Week Low
02/5/14 - $17.49
Market Cap
833.5M
Average Volume 10 Days
392.4K
EPS TTM
$0.40
Shares Outstanding
31.9M
EX-Date
--
P/E TM
64.8x
Dividend
--
Dividend Yield
--
Current Stock Chart for SAGENT PHARMACEUTICALS INC (SGNT)

Related News

No related news articles were found.

sagent pharmaceuticals inc (SGNT) Related Businessweek News

No Related Businessweek News Found

sagent pharmaceuticals inc (SGNT) Details

Sagent Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, sources, manufactures, and markets pharmaceutical products, principally injectable-based generic equivalents to branded products in the United States. The company offers anti-infective products, such as Cefepime, an antibiotic used to treat infections of the urinary tract, and skin and skin structures, as well as moderate to severe pneumonia, intra-abdominal infections, and as empiric therapy for febrile neutropenic patients; and Levofloxacin, a fluoroquinolone antibacterial for the treatment of infections caused by susceptible bacteria, including nosocomial and community acquired pneumonia, sinusitis, chronic bronchitis, skin and skin structure infections, prostatitis, urinary tract infection, and pyelonephritis in adults of age 18 years or older. It also provides oncology products consisting of Docetaxel, an antineoplastic agent used to treat advanced or metastatic breast cancer after chemotherapy failure; Leucovorin Calcium, a folic acid derivative used to prevent harmful effects of methotrexate when methotrexate is used to treat certain types of cancer; and Zoledronic Acid, a bisphosphonate given intravenously to prevent skeletal fractures in patients with cancers such as multiple myeloma and prostate cancer, as well as for treating osteoporosis. In addition, the company offers critical care products comprising Heparin, an anticoagulant used to prevent and treat blood clotting during and after surgery and dialysis. As of December 31, 2013, its product portfolio included 53 marketed products. It sells its products to hospitals, integrated delivery networks, and alternative site facilities through pharmaceutical wholesalers and specialty distributors. The company was formerly known as Sagent Holding Co. and changed its name to Sagent Pharmaceuticals, Inc. in April 2011. Sagent Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Schaumburg, Illinois.

269 Employees
Last Reported Date: 03/7/14
Founded in 2006

sagent pharmaceuticals inc (SGNT) Top Compensated Officers

Founder, Chairman and Chief Executive Officer
Total Annual Compensation: $615.2K
President
Total Annual Compensation: $308.7K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $330.8K
Chief Legal Officer, Executive Vice President...
Total Annual Compensation: $312.7K
Executive Vice President of National Accounts...
Total Annual Compensation: $287.4K
Compensation as of Fiscal Year 2013.

sagent pharmaceuticals inc (SGNT) Key Developments

SGNT Seeks Acquisitions

Sagent Pharmaceuticals, Inc. (NasdaqGS:SGNT) is seeking acquisitions. SGNT has filed a shelf registration in the amount of $373 million. SGNT intend to use the net proceeds from any sale of securities we offer under this prospectus for general corporate purposes, which may include working capital, capital expenditures, acquisitions and other strategic initiatives and repayment of indebtedness.

Sagent Pharmaceuticals, Inc. Announces Un-Audited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014; Narrows Net Income Guidance for Fiscal Year 2014

Sagent Pharmaceuticals, Inc. announced un-audited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported net revenue of $65.4 million, an increase of $4.5 million, or 7%, compared to $60.8 million in the third quarter of 2013. The increase was driven by $12.8 million in revenue from the launch of 29 new codes or presentations of 11 new products since September 30, 2013, partially offset by declines in the base business primarily related to price. The company reported income from operations of $4.0 million compared to $3.1 million, income before income taxes of $3.3 million compared to $2.8 million, net income of $1.9 million or $0.06 per diluted share compared to $2.8 million or $0.10 per diluted share and adjusted EBITDA of $7.2 million compared to $6.2 million for the last year. For the nine months, the company reported revenue of $205.4 million compared to $180.6 million, income from operations of $14.0 million compared to $26.4 million, income before income taxes of $12.9 million compared to $26.0 million, net income of $10.1 million or $0.31 per diluted share compared to $26.0 million or $0.90 per diluted share and adjusted EBITDA of $24.0 million compared to $33.6 million for the last year. Net revenue for the year 2014 to be in the range of $275 - $285 million driven by approximately ten product launches and the addition of Omega; Adjusted gross profit as a percentage of net revenue in the range of 30% to 33%. As a result, the company has narrowed its anticipated range for reported net income for fiscal 2014 to between $5 million and $10 million, before the impact of purchase accounting and other non-recurring costs.

Sagent Pharmaceuticals, Inc. to Report Q3, 2014 Results on Nov 04, 2014

Sagent Pharmaceuticals, Inc. announced that they will report Q3, 2014 results at 9:00 AM, US Eastern Standard Time on Nov 04, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SGNT:US $26.12 USD +1.95

SGNT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Lannett Co Inc $44.15 USD -0.72
OraSure Technologies Inc $10.53 USD +0.73
Pfizer Ltd/India 2,051 INR +50.45
SciClone Pharmaceuticals Inc $8.85 USD -0.22
Sucampo Pharmaceuticals Inc $13.57 USD +0.13
View Industry Companies
 

Industry Analysis

SGNT

Industry Average

Valuation SGNT Industry Range
Price/Earnings 62.5x
Price/Sales 3.1x
Price/Book 3.3x
Price/Cash Flow 61.0x
TEV/Sales 2.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SAGENT PHARMACEUTICALS INC, please visit www.sagentpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.